01 May 2013

Advice to the sellers in the sale of GlaxoSmithKline (GSK)to Okairos

VISCHER advises Okairos and selling shareholders (including BioMedInvest, LSP, Novartis Venture Funds) in the sale of Okairos AG, a Swiss developer of vaccine technologies, to GlaxoSmithKline Plc for EUR 250 Mio. The team at VISCHER is led by Matthias Staehelin (Corporate), Nadia Tarolli (Tax) with Roberto Peduzzi, Melanie Knüsel and Eric Flückiger.

Share article on:

Service(s) included:

Get in touch with our authors and benefit from their expertise:

partner-Matthias-0

Matthias Staehelin

matthias.staehelin@vischer.com

+41 58 211 33 53

partner-Nadia-1

Nadia Tarolli Schmidt

nadia.tarolli@vischer.com

+41 58 211 33 54

Our
newsletter

Advice to the sellers in the sale of GlaxoSmithKline (GSK)to Okairos